[1] Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition[J]. Pharmacol Review, 2004, 56(3):387-437. [2] Costa C, Soares R, Reis-Filho JS, et al. Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer[J]. J Clin Pathol ,2002,55(6):429-434. [3] Larkins TL, Nowell M, Singh S, et al. Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression[J]. BMC Cancer, 2006 ,6: 181. [4] Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of non-steroidal anti-inflammatory drugs[J]. A meta-analysis Ann Intern Med, 1991, 115(10): 787-796. [5] Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia[J]. Ann Clin Lab Sci,2000, 30(1):3-21. [6] Kurihara Y, Hatori M, Ando Y, et al. Inhibition of cyclooxygenase-2 suppresses the invasiveness of oral squamous cell carcinoma cell lines via down-regulation of matrix metalloproteinase-2 production and activation[J]. Clin Exp Metastasis, 2009,26(5):425-432. [7] Zhang GS, Liu DS, Dai CW,et al. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of COX-2 expression and are synergistic with hydroxyurea or imatinib[J].Am J Hematol,2006, 81(4):242-255. [8] 张广森,刘定胜.选择性COX-2抑制剂celecoxib对K562细胞的增殖抑制、凋亡诱导作用和分子机制[J]. 生物化学与生物物理进展,2004,31(12):1058-1065. [9] Kargman S, Wong E, Greig GM, et al. Mechanism of selective inhibition of human prostaglandin G/H synthase-1 and -2 in intact cells[J]. Biochem Pharmacol, 1996, 52(7):1113-1125. [10] Seibert K, Masferrer J, Needleman P, et al. Pharmacological manipulation of cyclooxygenase-2 in the inflamed hydronephrotic kidney[J]. Br J Pharmacol,1996, 117(6):1016-1020. [11] Langman MJ, Cheng KK, Gilman EA, et al. Effect of anti-inflammatorydrugs on overall risk of common cancer: cose-control study in general practice research database[J].BMJ, 2000,320(7250): 1642-1646. [12] Steinbad G, Lynch PM, Phillips RK, et al. The effect of eclecoxib, a cyclooxygenase-2 inhibitor, in tamilial adenomatous polyposis[J]. N Engl J Med,2000,342(26): 1946-1952. [13] Peng HL, Zhang GS, Liu JH, et al. Dup-697, a specific COX-2 inhibitor, suppresses growth and induces apoptosis on K562 leukemia cells by cell-cycle arrest and caspase-8 activation[J].Ann Hematol,2008,87(2):121-129. [14] 张岭漪,张有成,傅生军.NS-398诱导肝癌细胞凋亡的实验研究[J].中国临床药理学与治疗学,2005,10(1):61-64. [15] Vermes I, Haanen C, Steffens-Nakken H, et al. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V[J]. J Immunol Methods,1995, 184(1):39-51. [16] Homburg CH, de Haas M, von dem Borne AE, et al. Human neutrophils lose their surface Fc gamma RIII and acquire Annexin V binding sites during apoptosis in vitro[J]. Blood,1995, 85(2):532-540. [17] Liu X, Yue P, Zhou Z, et al. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells[J]. J Natl Cancer Inst., 2004, 96(23):1769-1780. [18] Barnhart BC, Alappat EC, Peter ME. The CD95 type I/ type II model[J]. Semin Immunol ,2003 ,15 (3) :185-193. |